We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current WUXIF market cap is 2.15B. The company's latest EPS is CNY 23.8651 and P/E is 0.22.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 12.84B | 16.5B | 22.85B | 39.15B | 40.04B |
| Operating Income | 4.99B | 6.25B | 8.26B | 14.48B | 16.31B |
| Net Income | 1.85B | 2.96B | 5.1B | 8.81B | 9.61B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 29.24B | 46.29B | 55.13B | 64.69B | 73.67B |
| Total Liabilities | 11.83B | 13.57B | 16.37B | 17.76B | 18.15B |
| Total Equity | 17.41B | 32.72B | 38.76B | 46.93B | 55.52B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 2.92B | 3.97B | 4.59B | 10.62B | 13.39B |
| Investing | -4.97B | -8.78B | -4.84B | -9.69B | -7.56B |
| Financing | 1.56B | 9.89B | -1.72B | -1.28B | -3.94B |
| Market Cap | 2.15B |
| Price to Earnings Ratio | 0.22 |
| Price to Sales Ratio | 0.05 |
| Price to Cash Ratio | 0.22 |
| Price to Book Ratio | 0.04 |
| Dividend Yield | - |
| Shares Outstanding | 402.54M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 1.75k |
| 52 Week Change | -37.57% |
| 52 Week High | 12.6875 |
| 52 Week Low | 4.3501 |
| Spread (Intraday) | 0.81 (14.44%) |
| Company Name | Wuxi Apptec Co Ltd (PK) |
| Address |
no. 288 fute middle road waigaoqiao free trade zone shanghai 200131 |
| Website | https://www.wuxiapptec.com.cn |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
